EyePoint Pharmaceuticals所有資訊

貝雅維持EyePoint Pharmaceuticals(EYPT.US)買入評級，下調目標價至33美元

富途資訊11/11 20:31

JonesTrading維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價45美元

富途資訊11/11 20:31

H.C. Wainwright維持EyePoint Pharmaceuticals(EYPT.US)買入評級，下調目標價至22美元

富途資訊11/11 20:31

eyepoint pharmaceuticals被HC Wainwright和Co維持在買入

道瓊斯11/11 20:24

eyepoint pharmaceuticals股價目標由HC Wainwright & Co. 降至$22.00/股，原價爲$30.00

道瓊斯11/11 20:24

Chardan Capital維持對eyepoint pharmaceuticals的買入評級，並將目標股價上調至33美元

Benzinga11/09 06:16

TD Cowen維持EyePoint Pharmaceuticals(EYPT.US)買入評級，下調目標價至20美元

富途資訊11/08 01:30

eyepoint pharmaceuticals：臨床試驗進展及有望的中期數據推動了買入評級

TipRanks11/08 00:50

豐業銀行維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價18美元

富途資訊10/29 19:34

eyepoint pharmaceuticals被Chardan Capital維持爲買入

道瓊斯10/29 19:11

eyepoint pharmaceuticals 分析師評級

Benzinga10/29 19:00

第一資本維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價35美元

富途資訊10/28 23:32

JonesTrading首次給予EyePoint Pharmaceuticals(EYPT.US)買入評級，目標價45美元

富途資訊10/28 22:32

貝雅維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價38美元

富途資訊10/25 23:34

eyepoint pharmaceuticals分析師評級

Benzinga10/25 22:02

H.C. Wainwright維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價30美元

富途資訊10/25 18:31

eyepoint pharmaceuticals前景樂觀：DURAVYU在LUGANO三期試驗中提升買入評級

TipRanks10/25 18:20

第一資本維持EyePoint Pharmaceuticals(EYPT.US)買入評級，維持目標價35美元

富途資訊10/25 04:32

加拿大豐業銀行開始對眼點製藥進行覆蓋，並給出板塊表現評級，宣佈目標股價爲18美元

Benzinga10/16 22:34

瑞穗證券維持EyePoint Pharmaceuticals(EYPT.US)買入評級

富途資訊10/11 16:31